Use of alkanoyl L-carnitines for the therapeutical treatment of chronic inflammatory bowel disease
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorClaudio Cavazza
Life of this patent
Estimating the term…
Abstract
The use of lower alkanoyl L-carnitines is disclosed for preparing pharmaceutical compositions (particularly foams and enemas) for treating chronic inflammatory bowel diseases, in particular ulcerative colitis.
Claims6
A rectally administrable pharmaceutical composition for the treatment of a chronic inflammatory bowel disease consisting of 5 to 10 grams of an alkanoyl L-carnitine in 500 ml of physiological solution wherein said alkanoyl group is straight or branched and contains 2-6 carbon atoms, and the pharmacologically acceptable salts thereof, said pharmaceutical composition further comprising a pharmacologically acceptable excipient.
Dependencies are inferred from the claim text.